CN115916189A - 治疗严重急性呼吸综合征的方法 - Google Patents

治疗严重急性呼吸综合征的方法 Download PDF

Info

Publication number
CN115916189A
CN115916189A CN202180031027.5A CN202180031027A CN115916189A CN 115916189 A CN115916189 A CN 115916189A CN 202180031027 A CN202180031027 A CN 202180031027A CN 115916189 A CN115916189 A CN 115916189A
Authority
CN
China
Prior art keywords
dantrolene
administering
subject
sars
host cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180031027.5A
Other languages
English (en)
Chinese (zh)
Inventor
阿德里安·赫普纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eagle Pharmaceuticals Inc
Original Assignee
Eagle Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eagle Pharmaceuticals Inc filed Critical Eagle Pharmaceuticals Inc
Publication of CN115916189A publication Critical patent/CN115916189A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202180031027.5A 2020-04-10 2021-04-08 治疗严重急性呼吸综合征的方法 Pending CN115916189A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063008529P 2020-04-10 2020-04-10
US63/008,529 2020-04-10
US202063062623P 2020-08-07 2020-08-07
US63/062,623 2020-08-07
PCT/US2021/026303 WO2021207444A1 (en) 2020-04-10 2021-04-08 Methods of treating severe acute respiratory syndrome

Publications (1)

Publication Number Publication Date
CN115916189A true CN115916189A (zh) 2023-04-04

Family

ID=75690705

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180031027.5A Pending CN115916189A (zh) 2020-04-10 2021-04-08 治疗严重急性呼吸综合征的方法

Country Status (11)

Country Link
US (1) US12582633B2 (https=)
EP (1) EP4132516A1 (https=)
JP (1) JP2023521162A (https=)
KR (1) KR20220167292A (https=)
CN (1) CN115916189A (https=)
AU (1) AU2021254415A1 (https=)
BR (1) BR112022020107A2 (https=)
CA (1) CA3174684A1 (https=)
IL (1) IL296518A (https=)
MX (1) MX2022012707A (https=)
WO (1) WO2021207444A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12605364B2 (en) * 2020-04-10 2026-04-21 Eagle Pharmaceuticals, Inc. Methods of treating SARS-CoV-2 infections

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY201417A (en) 2017-10-20 2024-02-21 Eagle Res Labs Limited Dantrolene prodrugs and methods of their use
US11123328B2 (en) 2017-11-14 2021-09-21 University Health Network Dantrolene and analogs thereof for the chronic treatment and prevention of dyssynchronous cardiac dysfunction
WO2019175761A1 (en) 2018-03-12 2019-09-19 Orbicular Pharmaceutical Technologies Private Limited Ready to use dantrolene compositions
US12246028B2 (en) 2018-11-27 2025-03-11 Eagle Research Labs Limited Use of dantrolene and dantrolene prodrugs to treat radiation exposure
US12605364B2 (en) 2020-04-10 2026-04-21 Eagle Pharmaceuticals, Inc. Methods of treating SARS-CoV-2 infections

Also Published As

Publication number Publication date
US12582633B2 (en) 2026-03-24
EP4132516A1 (en) 2023-02-15
WO2021207444A1 (en) 2021-10-14
CA3174684A1 (en) 2021-10-14
AU2021254415A1 (en) 2022-10-20
US20230149363A1 (en) 2023-05-18
IL296518A (en) 2022-11-01
BR112022020107A2 (pt) 2022-11-29
KR20220167292A (ko) 2022-12-20
MX2022012707A (es) 2023-01-05
JP2023521162A (ja) 2023-05-23

Similar Documents

Publication Publication Date Title
US11433080B2 (en) Antiviral treatment
US12582633B2 (en) Methods of treating severe acute respiratory syndrome
EP4132518B1 (en) Dantrolene for use in methods of treating sars-cov-2 infections
US20230225988A1 (en) Antiviral use of calixarenes
WO2022143710A1 (zh) 吡咯喹啉醌、其衍生物和/或盐作为抗病毒新药的用途及其药物组合物
CN112999235B (zh) 糖基聚醚化合物在制备抗副粘病毒或肠道病毒药物的用途
HK40090314A (zh) 治疗严重急性呼吸综合征的方法
EP4132519A1 (en) Methods of treating coronavirus infections
HK40083259B (en) Dantrolene for use in methods of treating sars-cov-2 infections
HK40083259A (en) Dantrolene for use in methods of treating sars-cov-2 infections
EP4132517A1 (en) Methods of treating viral infections
EA048350B1 (ru) Применение даларгина для профилактики орви и предотвращения развития осложнений при заболеваниях орви
KR20220009314A (ko) 사스-코로나바이러스-2 감염증 예방 또는 치료용 약학 조성물

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40090314

Country of ref document: HK